A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

The rarity of SOD1-ALS means however that tofersen is unlikely to make big sales, even if it has a high price. With Biogen squeezed between competitive pressures to its current multiple sclerosis ...

In-home care can be the most preferred option for patients with progressive diseases such as amyotrophic lateral sclerosis ...

Biogen Inc. has a Quality Score of 86, which is Very Strong ... Subscribe to A+ Investor Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks ...

Metalenses represent a revolutionary advancement in optical technology. Unlike conventional microscope objectives that rely ...

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq ... in potential milestone payments plus tiered royalties in the high single-digit to low double-digit range based on net sales.

Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose ...